



## **Momenta Pharmaceuticals Announces Date for 2005 Annual Meeting of Stockholders**

CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced that it will hold its Annual Meeting of Stockholders on May 26, 2005 at 8:30 am EDT at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA. Stockholders of record at the close of business on April 14, 2005 are entitled to vote at the Annual Meeting. Momenta mailed a notice of the annual Meeting and related proxy materials to stockholders of record on April 22, 2005.

### **About Momenta:**

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of sugar-based and biologic drug products. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit our website at <http://www.momentapharma.com>, which does not form a part of this press release.

### **Forward Looking Statements:**

Statements in this press release regarding Momenta Pharmaceuticals Inc.'s future expectations, beliefs, goals, plans or prospects constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Momenta's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in Momenta's Annual Report on Form 10-K for the year ended December 31, 2004 filed with the Securities and Exchange Commission under the section "Risk Factors that May Affect Results," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding Momenta's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "should", "will", and "would" or similar words. Momenta assumes no obligations to update the information included in this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Momenta Pharmaceuticals, Inc.

SOURCE Momenta Pharmaceuticals, Inc. -0- 04/25/2005 /CONTACT: Michael A. Lawless of Momenta Pharmaceuticals, Inc., +1-617-395-5189 / Web site: <http://www.momentapharma.com/> (MNTA)